Sanofi India Limited (SIL), a prominent player in the pharmaceutical industry, has announced significant changes in its leadership team, specifically in the role of Company Secretary and Compliance Officer.

Resignation of Arjun Thakkar

Mr. Arjun Thakkar, the current Company Secretary and Compliance Officer of Sanofi India Limited, has tendered his resignation effective September 30, 2025. Thakkar's decision to step down comes as he pursues a new career opportunity within the Sanofi Group, specifically in the Ethics & Business Integrity department.

The company has expressed its appreciation for Thakkar's contributions during his tenure. With his departure, Thakkar will also cease to be a Key Managerial Personnel and Senior Management Personnel of the company.

Appointment of Haresh Vala

In light of this transition, the Board of Directors of Sanofi India Limited, upon recommendation from the Nomination and Remuneration Committee, has approved the appointment of Mr. Haresh Vala as the new Company Secretary and Compliance Officer. Vala's appointment will be effective from October 1, 2025.

About Haresh Vala

Mr. Haresh Vala brings a wealth of experience to his new role at Sanofi India Limited:

• Professional Qualifications: Associate Member of the Institute of Company Secretaries of India
• Experience: Over two decades in corporate secretarial and compliance functions across diverse industries
• Education: Holds degrees in Law and Commerce from the University of Mumbai
• Expertise: Deep knowledge in corporate governance, regulatory compliance, investor relations, SEBI regulations, and Companies Act compliances
• Key Skills: Experienced in entity formation, capital structuring, fund-raising, dividend distribution, related party transactions, and compliance with LODR regulations

Vala's appointment is expected to strengthen Sanofi India's corporate governance framework and ensure compliance with regulatory requirements.

Additional Responsibilities

The Board has also authorized Mr. Haresh Vala to determine the materiality of events or information and make disclosures to the Stock Exchanges, in addition to other authorized Key Managerial Personnel. This responsibility is in line with Regulation 30(5) of the SEBI Listing Regulations.

Board Meeting Details

The decision regarding these leadership changes was made during a Board of Directors meeting held on September 25, 2025. The meeting commenced at 4:15 p.m. and concluded at 4:45 p.m.

These leadership changes at Sanofi India Limited reflect the company's commitment to maintaining strong corporate governance and ensuring smooth transitions in key roles. As the pharmaceutical industry continues to evolve, such strategic appointments are crucial for navigating regulatory landscapes and driving organizational growth.

Sanofi India Limited (SIL) has announced its financial results for the quarter ended June 30, 2025, revealing a mixed performance with challenges in sales but improvements in profitability.

Net Sales Decline

The company reported a 9.00% decline in net sales on a comparable basis of continuing business for the quarter. This decrease in sales highlights the challenges faced by the pharmaceutical sector in the current market environment.

Operating Profit Growth

Despite the decline in net sales, Sanofi India demonstrated resilience in its operations. For the year-to-date period ended June 2025, the company achieved a 6.00% increase in operating profit. This improvement is attributed to the company's focused approach to cost optimization and enhanced operational efficiencies.

Domestic Market Performance

In the domestic market, Sanofi India saw success with its diabetes treatment portfolio:

• The launch of Soliqua®, a premium diabetes treatment for the premix segment, continues to gain momentum.
• Toujeo®, another diabetes medication, maintained strong performance with high single-digit growth.

Strategic Partnerships

Sanofi India's strategic partnerships in the Cardiovascular (CV) and Central Nervous System (CNS) segments have established a solid foundation. These partnerships have met expectations for market reach expansion and business acceleration.

Export Challenges

The company's export sales were negatively impacted by two factors:

1. Non-recurring Consumer Healthcare (CHC) product sales from 2024
2. The planned discontinuation of the Zentiva portfolio

Management Commentary

Rachid Ayari, Whole Time Director and Chief Financial Officer of Sanofi India, commented on the results:

"During this transformative year for our company, our insulin portfolio has demonstrated robust growth, led by Toujeo® and the successful introduction of Soliqua®. Our strategic partnerships have effectively expanded our reach to healthcare professionals in both CV and CNS therapeutic areas, meeting our planned objectives. Moving forward, we remain committed to enhancing operational efficiency while broadening access to both our established products and innovative therapies across India."

Conclusion

Sanofi India continues to focus on its transformation strategy through targeted market initiatives, operational excellence, and innovation advancement in India. The company's efforts to optimize costs and enhance operational efficiencies have yielded positive results in terms of operating profit growth, despite the challenges in net sales.

As Sanofi India navigates through this transformative period, it aims to leverage its strong diabetes portfolio and strategic partnerships to drive growth and expand its market presence in key therapeutic areas.